Browse the evidence

Weekly subcutaneous Semaglutide 2.4 mg significantly reduces the risk of major adverse cardiovascular events (MACE) in patients with established cardiovascular disease and overweight or obesity, primarily by reducing non-fatal myocardial infarction.

If you have heart disease and are overweight, ask your doctor about Semaglutide 2.4mg. It is a weekly injection proven to lower your risk of heart attack and stroke significantly more than placebo, independent of just weight loss.

GLP-1 receptor agonists (Liraglutide, Semaglutide) and dual GIP/GLP-1 agonists (Tirzepatide) produce significant, sustained weight loss in adults with obesity or overweight with comorbidities, outperforming placebo.

If lifestyle changes haven't led to sufficient weight loss, consult a doctor about GLP-1 medications like Liraglutide or Semaglutide. These are prescribed for BMI ≥ 30 (or ≥ 27 with health issues) and work by mimicking gut hormones to reduce appetite and slow digestion. Treatment is most effective when combined with diet and exercise, and must be stopped if less than 5% weight loss occurs after 12 weeks.

Semaglutide (2.4 mg weekly) produces greater weight loss than Liraglutide (3.0 mg daily) in patients with obesity or overweight with comorbidities.

Semaglutide (2.4 mg weekly) is a highly effective treatment for obesity, producing greater weight loss than Liraglutide. It is administered once weekly via injection, with a dose titration from 0.25 mg to 2.4 mg. Due to high demand, supply shortages may occur, so availability should be checked with a healthcare provider.

Tirzepatide (5, 10, 15 mg weekly) produces substantial, dose-dependent weight loss in patients with obesity or overweight with comorbidities, outperforming placebo.

Tirzepatide is a dual GIP/GLP-1 agonist that produces significant, dose-dependent weight loss (up to 17.8% at 15 mg weekly). It is administered subcutaneously once weekly. As of September 2023, it was not approved for obesity treatment in Switzerland, so availability may be limited.

Weekly subcutaneous semaglutide (2.4 mg) produces significant weight loss (approx. 15%) and improves cardiovascular outcomes in adults with overweight or obesity, including those with heart failure with preserved ejection fraction (HFpEF).

If you have obesity, weekly semaglutide injections (2.4 mg) can help you lose about 15% of your body weight and significantly lower your risk of heart problems. This treatment is safe and effective for long-term use, unlike older drugs that were banned for causing heart issues.

Weekly subcutaneous tirzepatide (10-15 mg) produces greater weight loss (approx. 20-21%) than semaglutide in patients with obesity, with or without type 2 diabetes.

If you have obesity, weekly tirzepatide injections (10-15 mg) can help you lose about 20% of your body weight, which is more than semaglutide. This treatment is safe and effective for long-term use.

Tirzepatide (15 mg weekly) produces significantly greater weight loss than other market-available obesity medications, including semaglutide 2.4 mg, and achieves weight reduction comparable to bariatric surgery.

Tirzepatide is a highly effective, once-weekly injection for obesity that causes significantly more weight loss than other drugs like semaglutide and rivals bariatric surgery. However, it causes gastrointestinal side effects (nausea, diarrhea) which usually improve over time. It must be used alongside lifestyle changes because stopping the drug leads to rapid weight regain. Consult a doctor to manage side effects and determine if you are a candidate.

Anti-obesity medications (AOMs) including liraglutide, semaglutide, and tirzepatide demonstrate efficacy and safety for chronic weight management in randomized controlled trials lasting over one year.

If you are prescribed an FDA-approved anti-obesity medication like semaglutide or tirzepatide, expect it to be a long-term treatment. These drugs have been shown to be safe and effective for weight management over periods of 1-5 years in clinical trials. Because obesity is chronic, stopping the medication often leads to weight regain, so plan for ongoing use and address insurance/access issues early.

GLP-1 receptor agonists (GLP-1RAs) induce significant weight loss in adults with obesity or overweight by acting on the central nervous system to increase satiety and on the gastrointestinal tract to delay gastric emptying.

GLP-1 medications (like Semaglutide or Tirzepatide) are highly effective for weight loss, often achieving 15-25% body weight reduction in clinical trials. They work by reducing appetite and slowing digestion. These are prescription medications, not supplements. They require long-term use to maintain weight loss, as stopping often leads to regain. They are generally safe but can cause gastrointestinal side effects. Consult a doctor to see if you are a candidate.

Multi-receptor agonists (e.g., Tirzepatide, Retatrutide) achieve greater weight loss than single-target GLP-1RAs by simultaneously activating multiple gut hormone receptors (GLP-1R, GIPR, GCGR).

Newer 'multi-agonist' drugs like Tirzepatide and Retatrutide are even more effective for weight loss than older GLP-1 drugs, achieving up to 24% body weight loss in trials. They work by targeting multiple hormone receptors. They are taken once weekly. They are prescription medications and can cause gastrointestinal side effects.

GLP-1 receptor agonists (e.g., liraglutide, semaglutide) induce significant weight loss in individuals with obesity by suppressing appetite and reducing energy intake through central nervous system mechanisms.

GLP-1 receptor agonists like semaglutide and liraglutide are highly effective pharmacological interventions for obesity that work by targeting the biological drivers of weight gain, specifically by suppressing appetite and reducing energy intake. They are administered via injection (daily or weekly) and have shown substantial weight loss in clinical trials. For those who struggle with injections, oral alternatives are in development. While currently expensive and less accessible in some regions, they represent a significant advancement over lifestyle changes alone for managing obesity and its comorbidities.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual agonists (tirzepatide) are highly effective for weight loss and cardiovascular risk reduction in adults with obesity.

If lifestyle changes alone haven't worked, ask your doctor about GLP-1 medications like semaglutide or tirzepatide. These are injectable drugs that mimic hormones to reduce hunger and improve metabolism. They have been shown to produce significant weight loss (14-20%) and improve heart health markers.

New-generation incretin-based obesity medications (semaglutide 2.4 mg weekly and tirzepatide 5-15 mg weekly) achieve mean weight loss exceeding 10-15%, which is two- to three-fold greater than previous obesity medications.

If you have obesity, new medications like semaglutide (2.4 mg weekly) or tirzepatide (5-15 mg weekly) can help you lose 15% or more of your body weight, which is significantly more than older drugs. These are taken as weekly injections. Because obesity is a chronic condition, you likely need to stay on these medications long-term to maintain the weight loss, similar to how you manage blood pressure or diabetes with daily meds.

GLP-1 receptor agonists (semaglutide, tirzepatide) provide significant cardiovascular benefits, including a 20% reduction in major adverse cardiovascular events (MACE) in patients with obesity and pre-existing cardiovascular disease but without diabetes.

If you have obesity and existing heart disease, even without diabetes, taking semaglutide (2.4 mg weekly) can significantly lower your risk of heart attack, stroke, or cardiovascular death by about 20%. This benefit appears to come from the drug's direct effects on the body, not just from losing weight.

Tirzepatide, a dual GLP-1/GIP receptor agonist administered once weekly, significantly reduces body weight and improves glycemic control in patients with type 2 diabetes and obesity compared to placebo and other active comparators.

Tirzepatide is a once-weekly injection that helps your body manage blood sugar and lose weight more effectively than many existing treatments. It works by mimicking hormones that regulate appetite and insulin. You start with a low dose to minimize stomach upset and gradually increase it. It is approved for both type 2 diabetes and obesity management.

Modern GLP-1 receptor agonists (e.g., liraglutide) and combination therapies (e.g., phentermine/topiramate) offer significant, sustained weight loss with improved safety profiles compared to historical agents.

Modern obesity treatments like GLP-1 agonists (e.g., liraglutide) and combination therapies (e.g., phentermine/topiramate) are effective and safer than older drugs. They require medical supervision and are prescribed for specific patient profiles.

GLP-1 receptor agonists (semaglutide 2.4 mg) and dual GIP/GLP-1 agonists (tirzepatide 15 mg) produce significant weight loss (15–21%) and improve obesity-related comorbidities, but discontinuation leads to substantial weight regain, necessitating long-term maintenance therapy.

Use FDA-approved GLP-1 or dual agonists for significant obesity. These drugs work by mimicking gut hormones to reduce appetite and increase satiety. You must take them long-term; stopping leads to weight regain. Discuss titration schedules with your doctor to manage side effects like nausea.

Discontinuation of GLP-1/GIP agonist therapy leads to significant weight regain, indicating that obesity requires chronic pharmacological management rather than short-term courses.

If you stop taking these medications, you will likely regain the weight. Treat obesity like hypertension: it requires ongoing management. Do not stop without consulting your doctor.

Tirzepatide, a dual GLP-1 and GIP receptor agonist, produces superior total body weight loss (up to 20.9% at 72 weeks) compared to placebo and other anti-obesity medications.

Tirzepatide is a highly effective weekly injection for obesity, achieving nearly 21% weight loss in clinical trials. It works by mimicking hormones that regulate hunger and digestion. While effective, it requires weekly injections and can cause gastrointestinal side effects like nausea.

Semaglutide, a GLP-1 receptor agonist, produces significant weight loss (up to 15.8% at 68 weeks) and improves cardiovascular outcomes in patients with obesity or type 2 diabetes.

Semaglutide is a highly effective weekly injection for obesity and type 2 diabetes, achieving nearly 15% weight loss in clinical trials. It works by mimicking the GLP-1 hormone, which regulates hunger and digestion. It also offers cardiovascular benefits, reducing the risk of heart attack and stroke.

GLP-1 receptor agonists (e.g., semaglutide 2.4 mg) produce clinically significant weight loss and reduce major adverse cardiovascular events (MACE) in adults with obesity or overweight, regardless of diabetes status.

GLP-1 medications like semaglutide are highly effective for weight loss and heart health, even if you don't have diabetes. While injections are common, oral versions exist. Be aware that cost and side effects (like nausea) can make sticking with the treatment difficult, so discuss these barriers with your doctor early.

Semaglutide (2.4 mg weekly) produces superior weight loss (14.9%) and significant cardiovascular risk reduction compared to placebo and other anti-obesity drugs.

If you have obesity and cardiovascular risks, semaglutide (2.4 mg weekly) is currently the most effective FDA-approved pharmacotherapy, offering significant weight loss and heart protection. Start with the lowest dose (0.25 mg) and titrate up to manage side effects. An oral version exists if you prefer avoiding injections.

Tirzepatide (up to 15 mg weekly) achieves the highest mean weight loss (up to 20.9%) among current pharmacotherapies but lacks FDA approval for cardiovascular risk reduction.

Tirzepatide (up to 15 mg weekly) offers the highest weight loss potential (up to 20.9%) among current drugs. However, it is not yet FDA-approved for cardiovascular risk reduction. Titrate the dose slowly to manage gastrointestinal side effects.

Dual GLP-1/GIP agonist tirzepatide (10-15 mg/week) produces superior weight loss (approx. 20.2%) compared to semaglutide (2.4 mg/week, approx. 13.7%) in patients with obesity.

If you are struggling with obesity and other treatments have failed, ask your doctor about tirzepatide. It is a weekly injection that targets hunger hormones and has been shown to produce greater weight loss than semaglutide. Be prepared for potential stomach issues, which usually improve over time, especially if the dose is increased slowly.